fluticasone propionate

Small molecule

Also known as FP 100

Approvedregulatory verdict

Evidence outlook

Approved: Asthma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
CA
  • Flovent (HFA and Diskus): prophylactic management of steroid-responsive bronchial asthma in adults and children 12 months of age or older
Product first approved 1995pdf.hres.ca

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (48)
Asthma
NCT06664619 · Teva Branded Pharmaceutical Products R&D LLC
2024-12-12 – 2026-10-26 · Asthma
What this study did
NCT05363202 · Glenmark Pharmaceuticals Ltd. India
2022-04-15 – 2024-08-30 · Bronchial Asthma
What this study did
NCT03879837 · Actavis Inc.
2019-03-25 – 2021-07-09 · Asthma
What this study did
NCT03562923 · Amneal Ireland Limited
2018-10 – 2019-06 · Asthma
What this study did
NCT02980133 · Teva Branded Pharmaceutical Products R&D, Inc.
2016-12-28 – 2019-04-13 · Asthma
What this study did
NCT02141854 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-06 – 2015-09 · Asthma
What this study did
NCT02139644 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-06 – 2015-09 · Asthma
What this study did
NCT02175771 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-07 – 2015-07 · Persistent Asthma
What this study did
NCT01606306 · Milton S. Hershey Medical Center
2013-02 – 2015-04 · Asthma, Wheezing
What this study did
NCT01687283 · GlaxoSmithKline
2012-09-27 – 2013-11-07 · Asthma
What this study did
NCT01511367 · Mundipharma Research Limited
2012-03 – 2013-11 · Asthma
What this study did
NCT01687296 · GlaxoSmithKline
2012-11-12 – 2013-06-21 · Asthma
What this study did
NCT01435902 · GlaxoSmithKline
2012-01 – 2012-08 · Asthma
What this study did
NCT00395304 · Milton S. Hershey Medical Center
2007-03 – 2011-12 · Asthma
What this study did
NCT00127166 · Organon and Co
2005-12 – 2008-11 · Exercise Induced Asthma
What this study did
NCT00475813 · Mundipharma Research Limited
2007-03 – 2008-02 · Asthma
What this study did
NCT00476073 · Mundipharma Research Limited
2007-04 – 2008-01 · Asthma Bronchiale
What this study did
NCT00394121 · SkyePharma AG
2006-03 – 2007-07 · Asthma
What this study did
NCT00489346 · Organon and Co
2001-10 – 2002-06 · Asthma, Bronchial
What this study did
Other / comorbidity
NCT06234345 · Eurofarma Laboratorios S.A.
2027-01-30 – 2028-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT07582549 · Tampere University Hospital
2025-12-22 – 2027-12 · Chronic Cough
What this study did
NCT04655508 · Assistance Publique - Hôpitaux de Paris
2021-05-21 – 2023-09-27 · Stem Cell Transplant Complications, Respiratory Disease, Bronchiolitis Obliterans
What this study did
NCT04332978 · Libbs Farmacêutica LTDA
2014-07-04 – 2020-04-01 · Perennial Allergic Rhinitis
What this study did
NCT03591068 · Optinose US Inc.
2018-06-07 – 2019-02-22 · Nasal Polyposis
What this study did
NCT02523820 · Ramathibodi Hospital
2015-01 – 2016-08-30 · Stridor
What this study did
NCT01623310 · Optinose US Inc.
2013-09 – 2015-10 · Nasal Polyps
What this study did
NCT01624662 · Optinose US Inc.
2013-10-30 – 2015-07-03 · Bilateral Nasal Polyposis
What this study did
NCT02230696 · Padagis LLC
2014-08 – 2015-02 · Seasonal Allergic Rhinitis
What this study did
NCT02246920 · Teva Pharmaceuticals USA
2014-03-01 – 2014-07-14 · Seasonal Allergic Rhinitis
What this study did
NCT01915823 · Meda Pharmaceuticals
2013-07 – 2014-02 · Seasonal Allergic Rhinitis
What this study did
NCT01794741 · Meda Pharmaceuticals
2013-02 – 2013-11 · Allergic Rhinitis
What this study did
NCT01817790 · GlaxoSmithKline
2012-12 – 2013-02 · Allergic Rhinitis, Seasonal Allergic Rhinitis
What this study did
NCT00266578 · Marc Rothenberg
2002-10 – 2012-10 · Eosinophilic Esophagitis
What this study did
NCT00883168 · Meda Pharmaceuticals
2009-04 – 2009-07 · Seasonal Allergic Rhinitis
What this study did
NCT00740792 · Meda Pharmaceuticals
2008-08 – 2008-11 · Seasonal Allergic Rhinitis
What this study did
NCT00651118 · Meda Pharmaceuticals
2008-03 – 2008-07 · Seasonal Allergic Rhinitis
What this study did
NCT00398476 · GlaxoSmithKline
2006-12-01 – 2006-12-04 · Rhinitis, Allergic, Perennial
What this study did
NCT00549146 · GlaxoSmithKline
2003-11 – 2006-04 · Pulmonary Disease, Chronic Obstructive
What this study did
Phase 2/3 (6)
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
NCT05054322 · University of Medicine and Pharmacy at Ho Chi Minh City
2021-09-22 – 2022-08-30 · Covid19
What this study did
NCT04242368 · Stanford University
2020-07-01 – 2021-07-01 · Chronic Rhinosinusitis (Diagnosis)
What this study did
NCT02778867 · Children's Hospital Medical Center, Cincinnati
2016-05-20 – 2019-05-29 · Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis (EoE)
What this study did
NCT02610816 · Children's Hospital Medical Center, Cincinnati
2016-03-21 – 2018-05-16 · Eosinophilic Esophagitis, Eosinophilic Gastrointestinal Disorders (EGIDs)
What this study did
NCT02693769 · Mundipharma Research Limited
2016-07 – 2016-12 · ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)
What this study did
Phase 2 (33)
Asthma
NCT02740543 · NYU Langone Health
2013-12 – 2019-10-23 · Asthma
What this study did
NCT04179461 · Children's Hospital Medical Center, Cincinnati
2018-03-16 – 2019-10-03 · Asthma in Children
What this study did
NCT02991859 · GlaxoSmithKline
2017-02-09 – 2018-12-20 · Asthma
What this study did
NCT01563029 · GlaxoSmithKline
2012-03-28 – 2014-09-24 · Asthma
What this study did
NCT01573767 · GlaxoSmithKline
2012-04 – 2014-04 · Asthma
What this study did
NCT01516086 · Dey
2012-03 – 2013-11 · Asthma
What this study did
NCT01516073 · Dey
2012-03 – 2013-11 · Asthma
What this study did
NCT01772368 · Teva Branded Pharmaceutical Products R&D, Inc.
2013-01 – 2013-06 · Asthma
What this study did
NCT01400906 · GlaxoSmithKline
2011-07-20 – 2012-12-12 · Asthma
What this study did
NCT01253603 · Novartis Pharmaceuticals
2010-11 – 2011-09 · Persistent Asthma
What this study did
NCT00995800 · Mundipharma Research Limited
2009-10 – 2010-07 · Asthma
What this study did
NCT00734292 · SkyePharma AG
2008-09 – 2008-10 · Mild to Moderate Asthma
What this study did
NCT00400855 · GlaxoSmithKline
2005-01 – 2005-08 · Asthma
What this study did
Other / comorbidity
NCT05275686 · Cedars-Sinai Medical Center
2022-04-20 – 2027-12-31 · Eustachian Tube Dysfunction
What this study did
NCT05922761 · Dana-Farber Cancer Institute
2024-05-31 – 2027-12-31 · Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
What this study did
NCT03926026 · Nicox Ophthalmics, Inc.
2019-03-18 – 2019-10-21 · Blepharitis
What this study did
NCT01307462 · Stephanie Lee
2011-06 – 2015-12 · Bronchiolitis Obliterans
What this study did
NCT01712451 · Neothetics, Inc
2011-08 – 2012-10 · Abdominal Contour Defects
What this study did
NCT00426283 · Marc Rothenberg, MD
2007-01 – 2012-03 · Eosinophilic Esophagitis
What this study did
NCT01168310 · Dey
2010-08 – 2011-10 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00656916 · M.D. Anderson Cancer Center
2008-03 – 2010-12 · Bronchiolitis
What this study did
NCT00275561 · Mayo Clinic
2005-11 – 2010-04 · Eosinophilic Esophagitis
What this study did
NCT00774761 · Dey
2008-11 – 2009-05 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00612820 · GlaxoSmithKline
2008-01 – 2008-05 · Rhinitis, Allergic, Seasonal
What this study did
NCT00241631 · Imperial College London
2006-04 – 2007-08 · COPD
What this study did
NCT00403286 · Dey
2006-11 – 2007-05 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00400998 · Research Consult GmbH
2006-03 – 2006-11 · Allergic Rhinitis, Rhinitis, Allergic, Seasonal
What this study did
NCT00407264 · Amsterdam UMC, location VUmc
2002-02 – 2005-12 · Bronchogenic Carcinoma
What this study did
Phase 1 (23)
Asthma
NCT01966692 · University of Florida
2016-11 – 2018-01-20 · Asthma
What this study did
NCT02466503 · Intech Biopharm Ltd.
2014-08 – 2014-09 · Asthma, Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02466347 · Intech Biopharm Ltd.
2014-06 – 2014-08 · Asthma, Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00370097 · GlaxoSmithKline
2006-08-30 – 2007-04-12 · Asthma
What this study did
Other / comorbidity
NCT07918404 · Dianosic
2026-11 – 2027-12 · Chronic Allergic Rhinitis
What this study did
NCT06180083 · Humanis Saglık Anonim Sirketi
2023-03-24 – 2023-07-05 · Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
What this study did
NCT03040596 · Joseph Dohar, MD
2017-03-01 – 2019-01-23 · Vocal Fold Nodules
What this study did
NCT03594565 · Assaf-Harofeh Medical Center
2016-03 – 2018-06 · T1DM, Hypersensitivity
What this study did
NCT02232087 · Kindeva Drug Delivery
2014-07 – 2014-12 · Healthy
What this study did
NCT01364519 · Pfizer
2011-07 – 2012-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01449799 · GlaxoSmithKline
2011-07-13 – 2011-09-21 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00869596 · Merck Sharp & Dohme LLC
2009-03 – 2009-09 · Airway Inflammation
What this study did
NCT00348361 · GlaxoSmithKline
started 2005-04 · Allergic Rhinitis
What this study did
NCT01365611 · Egalet Ltd
2007-02 – 2008-03 · Healthy Subjects
What this study did
NCT00404586 · GlaxoSmithKline
2006-09-11 – 2007-01-16 · Rhinitis, Allergic, Perennial
What this study did
NCT00280358 · Dey
est. completion 2005-12 · Healthy
What this study did
Phase 4 (58)
Asthma
NCT07664527 · University of Wisconsin, Madison
2026-11 – 2027-09 · Asthma
What this study did
NCT04953741 · Xijing Hospital
2021-08-01 – 2022-08-01 · Asthma in Children
What this study did
NCT01554488 · VA Office of Research and Development
2013-03-12 – 2016-04-07 · Asthma, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea
What this study did
NCT01741285 · University Medical Center Groningen
2013-04 – 2015-12 · Asthma
What this study did
NCT00995657 · University of Dundee
2009-10 – 2011-12 · Asthma
What this study did
NCT00692978 · Imperial College London
2008-08 – 2011-07-03 · Healthy, Asthma
What this study did
NCT00712335 · Inje University
2007-02 – 2011-05 · Asthmatic Smokers, Non-asthmatic Smokers
What this study did
NCT01192178 · GlaxoSmithKline
2010-08 – 2010-12 · Asthma
What this study did
NCT00716963 · Hamilton Health Sciences Corporation
2008-07 – 2008-12 · Mild Intermittent Asthma
What this study did
NCT00197106 · GlaxoSmithKline
2005-06 – 2008-10 · Asthma
What this study did
NCT00903227 · University of Dundee
2006-12 – 2008-08 · Asthma, Allergic Rhinitis
What this study did
NCT00503009 · GlaxoSmithKline
2007-10 – 2008-07 · Asthma
What this study did
NCT00517634 · GlaxoSmithKline
2007-08 – 2008-07 · Asthma
What this study did
NCT00456313 · GlaxoSmithKline
2007-12 – 2007-12 · Asthma
What this study did
NCT00461500 · GlaxoSmithKline
2007-03 – 2007-12 · Asthma
What this study did
NCT00455923 · GlaxoSmithKline
2005-05-03 – 2007-07-31 · Asthma
What this study did
NCT00296530 · GlaxoSmithKline
2005-09 – 2007-07 · Asthma
What this study did
NCT00102765 · GlaxoSmithKline
2004-11 – 2007-04 · Asthma
What this study did
NCT00353873 · GlaxoSmithKline
2005-11-18 – 2006-10-26 · Asthma
What this study did
NCT00118716 · GlaxoSmithKline
2003-12-23 – 2006-04-23 · Bronchospasm, Activity/Exercise Induced Bronchospasm
What this study did
NCT00453778 · GlaxoSmithKline
2002-11 – 2004-05 · Asthma, Mild Asthma
What this study did
Other / comorbidity
NCT07675252 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2026-08-01 – 2027-06-30 · Acute Wheezing Disorders in Infants Aged 0 to 24 Months
What this study did
NCT07817134 · HALEON
2026-09 – 2026-12 · Rhinitis Allergic, Rhinitis Seasonal
What this study did
NCT02476825 · University Hospitals, Leicester
2016-01-20 – 2026-10-31 · Healthy
What this study did
NCT07415278 · Pamukkale University
2022-12-01 – 2026-10-30 · Allergic Rhinitis
What this study did
NCT07597473 · Viatris Inc.
2026-05-08 – 2026-10-13 · Allergic Rhinitis Due to Allergens
What this study did
NCT02630121 · University of South Florida
2023-04-01 – 2026-04 · Sleep Apnea, Chronic Nasal Congestion
What this study did
NCT06858423 · Benha University
2023-08-15 – 2024-05-31 · Nasal Allergy
What this study did
NCT05444543 · University Hospitals Cleveland Medical Center
2021-11-17 – 2023-10-13 · Eosinophilic Esophagitis
What this study did
NCT05314621 · Andover Research Eye Institute
2021-12-31 – 2022-07-24 · Allergic Conjunctivitis
What this study did
NCT04652245 · MEDA Pharma GmbH & Co. KG
2020-12-14 – 2021-12-13 · Seasonal Allergic Rhinitis
What this study did
NCT04957927 · Usama Azhar
2020-12-12 – 2021-12-12 · Allergic Rhinitis
What this study did
NCT04601324 · St. Paul's Sinus Centre
2020-12-15 – 2021-07-01 · Allergic Rhinitis
What this study did
NCT02402465 · University of Chicago
2015-02 – 2020-02 · Allergic Rhinitis
What this study did
NCT03004131 · MEDA Pharma GmbH & Co. KG
2017-01-07 – 2017-03-29 · Seasonal Allergic Rhinitis
What this study did
NCT00846326 · Brian J Lipworth
— · Allergic Rhinitis, Tachyphylaxis, Rhinitis Medicamentosa
What this study did
NCT02338362 · University Health Network, Toronto
2014-09 – 2015-02 · Ocular Hypertension, Glaucoma, Open-Angle
What this study did
NCT01916226 · GlaxoSmithKline
2013-08-01 – 2013-10-17 · Rhinitis, Allergic, Perennial and Seasonal
What this study did
NCT00975195 · Boehringer Ingelheim
2009-02 – 2013-07 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01439815 · ORA, Inc.
2011-09 – 2011-10 · Allergic Rhinitis, Allergic Conjunctivitis
What this study did
NCT01103934 · University of Chicago
2010-06 – 2011-07 · Seasonal Allergic Rhinitis
What this study did
NCT00487032 · Brian J Lipworth
2008-05 – 2009-05 · Allergic Rhinitis, Tachyphylaxis, Rhinitis Medicamentosa
What this study did
NCT00119015 · University of Chicago
2005-07 – 2009-01 · Rhinitis, Allergic, Perennial
What this study did
Early phase / not applicable (10)
Asthma
NCT00409630 · University of Kansas
— · Asthma
What this study did
NCT00706446 · Brigham and Women's Hospital
2008-06 – 2011-09 · Asthma
What this study did
Other / comorbidity
NCT04171167 · Tampere University Hospital
2017-04-04 – 2026-12 · Chronic Rhinosinusitis (Diagnosis)
What this study did
NCT07537751 · Noura Abdelmoneim Mohammed Elseessy
2024-02-01 – 2025-03-01 · Atopic Dermatitis, Eczema
What this study did
NCT02024204 · NYU Langone Health
2014-04-09 – 2017-05-17 · Lung Diseases, Medication Compliance
What this study did
NCT02141633 · University of Miami
2013-04 – 2015-12 · Smoking
What this study did
NCT02290717 · Netherlands Institute for Pigment Disorders
2015-05 – 2015-11 · Vitiligo
What this study did
NCT02194062 · Yale University
2015-01 – 2015-08 · Sinusitis, Nasal Polyps
What this study did
NCT01400568 · Fraunhofer-Institute of Toxicology and Experimental Medicine
2011-08 – 2012-01 · Healthy
What this study did
NCT00755066 · Medical University of Vienna
— · Seasonal Allergic Rhinitis
What this study did
Used as active comparator (41)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (18)
Asthma
NCT01436110 · GlaxoSmithKline
2011-09 – 2012-09 · Asthma
What this study did
NCT01159912 · GlaxoSmithKline
2010-06-30 – 2012-01-16 · Asthma
What this study did
NCT01134042 · GlaxoSmithKline
2010-06 – 2011-10 · Asthma
What this study did
NCT01018186 · GlaxoSmithKline
2009-10-19 – 2011-05-12 · Asthma
What this study did
NCT00734318 · Mundipharma Research Limited
2008-09 – 2009-10 · Asthma, Bronchial
What this study did
NCT00158834 · GlaxoSmithKline
started 1999-11 · Asthma
What this study did
NCT00540839 · Organon and Co
2007-11 – 2008-03 · Asthma, Bronchial
What this study did
NCT00920959 · GlaxoSmithKline
2001-11 – 2004-01 · Asthma
What this study did
Other / comorbidity
NCT03599791 · MEDA Pharma GmbH & Co. KG
2018-06-29 – 2019-09-24 · Allergic Rhinitis
What this study did
NCT02249663 · Teva Pharmaceuticals USA
2014-08 – 2015-02 · Seasonal Allergic Rhinitis
What this study did
NCT00660517 · Meda Pharmaceuticals
2007-12 – 2008-04 · Seasonal Allergic Rhinitis
What this study did
NCT00783224 · Organon and Co
2005-09 – 2005-12 · Perennial Allergic Rhinitis
What this study did
NCT00641680 · AstraZeneca
2003-04 – 2003-07 · Seasonal Allergic Rhinitis
What this study did
NCT03882047 · Organon and Co
1994-08-11 – 1994-09-16 · Rhinitis, Allergic, Seasonal
What this study did
Phase 2 (10)
Asthma
NCT07324707 · Anhui Palo Alto Pharmaceuticals, Inc.
2025-10-15 – 2026-03 · Bronchial Asthma
What this study did
NCT01738087 · Chiesi Farmaceutici S.p.A.
2012-11 – 2013-01 · Asthmatic
What this study did
NCT01147744 · GlaxoSmithKline
2010-06-28 – 2011-10-06 · Asthma
What this study did
NCT01092143 · Boehringer Ingelheim
2010-03-18 – 2011-03-26 · Asthma
What this study did
NCT00814216 · Novartis
2008-12 – 2009-10 · Asthma
What this study did
Other / comorbidity
NCT01260753 · Palau Pharma S.L.U.
2010-12 – 2011-03 · Seasonal Allergic Rhinitis
What this study did
Phase 1 (2)
Asthma
NCT03112577 · Regeneron Pharmaceuticals
2017-06-15 – 2019-12-09 · Asthma, Allergic
What this study did
NCT00877539 · Pfizer
2009-06 – 2010-07 · Asthma
What this study did
Phase 4 (10)
Asthma
NCT03199976 · Helsinki University Central Hospital
2016-04-20 – 2020-11-18 · Wheezy Bronchitis, Asthmatic Bronchitis, Wheezing, Obstruction Airway
What this study did
NCT01462344 · GlaxoSmithKline
2011-11-17 – 2015-11-03 · Asthma
What this study did
NCT01526161 · Professor Warren Lenney
2009-04 – 2011-01 · Asthma
What this study did
NCT00830505 · University of Dundee
2009-04 – 2010-05 · Asthma
What this study did
NCT00315744 · GlaxoSmithKline
2004-11-04 – 2007-04-12 · Asthma
What this study did
Other / comorbidity
NCT00845598 · University of Dundee
2010-08 – 2011-08 · Allergic Rhinitis
What this study did
NCT00691665 · Alcon Research
2008-05 – 2009-01 · Seasonal Allergic Rhinitis
What this study did
NCT00616538 · Ceragenix Pharmaceuticals
2006-12 – 2007-04 · Atopic Dermatitis
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02883439 · University Hospital, Ghent
2016-08 – 2020-03 · Bioavailability Study
What this study did
Studied as part of a combination product (81)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (26)
Asthma
NCT03394989 · Cipla Ltd.
2018-10-17 – 2020-03-31 · Bronchial Asthma
What this study did
NCT03756883 · Actavis Inc.
2018-12-03 – 2019-11-10 · Asthma
What this study did
NCT02496715 · Actavis Inc.
2015-09 – 2016-12 · Asthma
What this study did
NCT02245672 · Mylan Pharma UK Ltd.
2014-10 – 2015-07 · Asthma
What this study did
NCT01147848 · GlaxoSmithKline
2010-06 – 2011-07 · Asthma
What this study did
NCT00448435 · GlaxoSmithKline
2007-04 – 2008-01 · Bronchial Asthma
What this study did
NCT00328718 · GlaxoSmithKline
2005-10 – 2007-04 · Asthma
What this study did
NCT00394368 · Chiesi Farmaceutici S.p.A.
2004-11 – 2005-09 · Bronchial Asthma
What this study did
Other / comorbidity
NCT00411372 · GlaxoSmithKline
started 2006-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01817764 · GlaxoSmithKline
2013-03-01 – 2013-10-25 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01772134 · GlaxoSmithKline
2013-01-01 – 2013-07-22 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00269087 · GlaxoSmithKline
2005-01-28 – 2006-10-25 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00268216 · GlaxoSmithKline
2000-09 – 2005-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00269126 · GlaxoSmithKline
2005-02 – 2005-08 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00268177 · GlaxoSmithKline
2002-10 – 2003-12 · Pulmonary Disease, Chronic Obstructive
What this study did
Phase 2 (5)
Asthma
NCT03207243 · GlaxoSmithKline
2017-09-14 – 2019-05-15 · Asthma
What this study did
NCT02573233 · Sanofi
2016-01-27 – 2018-01-03 · Asthma
What this study did
NCT00369993 · GlaxoSmithKline
2005-03 – 2005-05 · Asthma
What this study did
Phase 1 (21)
Asthma
NCT02680561 · Teva Branded Pharmaceutical Products R&D, Inc.
2016-04 – 2016-08 · Asthma
What this study did
NCT02260492 · Oriel Therapeutics
2014-09 – 2015-07 · Asthma
What this study did
NCT01890863 · GlaxoSmithKline
2013-08-05 – 2013-09-30 · Asthma
What this study did
NCT00364442 · GlaxoSmithKline
2005-01-28 – 2005-04-13 · Asthma
What this study did
Other / comorbidity
NCT05982990 · Respirent Pharmaceuticals Co Ltd.
2023-08-01 – 2023-11-20 · Bioequivalence
What this study did
NCT06025214 · Respirent Pharmaceuticals Co Ltd.
2023-08-22 – 2023-10-31 · Bioequivalence
What this study did
NCT05697003 · Respirent Pharmaceuticals Co Ltd.
2023-02-17 – 2023-05-01 · Bioequivalence
What this study did
NCT04124094 · Respirent Pharmaceuticals Co Ltd.
2019-10-01 – 2020-06-09 · Bioequivalence
What this study did
NCT03894280 · Respirent Pharmaceuticals Co Ltd.
2019-03-12 – 2019-05-06 · Bioequivalence
What this study did
NCT03751202 · Respirent Pharmaceuticals Co Ltd.
2018-11-20 – 2018-12-11 · Bioequivalence
What this study did
NCT01564199 · Orion Corporation, Orion Pharma
2012-04 – 2012-06 · Healthy Volunteer Study
What this study did
Phase 4 (26)
Asthma
NCT04677959 · Teva Branded Pharmaceutical Products R&D, Inc.
2021-02-16 – 2022-03-10 · Asthma
What this study did
NCT00296491 · GlaxoSmithKline
2005-09 – 2007-10 · Asthma
What this study did
NCT00291382 · GlaxoSmithKline
2005-11 – 2007-07 · Asthma
What this study did
NCT00351143 · GlaxoSmithKline
2005-07-26 – 2007-06-13 · Asthma
What this study did
NCT00102882 · GlaxoSmithKline
2004-10 – 2007-01 · Asthma
What this study did
NCT00273026 · GlaxoSmithKline
2004-11-08 – 2006-03-28 · Asthma
What this study did
NCT00118690 · GlaxoSmithKline
2003-12 – 2005-12 · Bronchospasm, Activity/Exercise Induced Bronchospasm
What this study did
NCT00480649 · GlaxoSmithKline
2004-01 – 2005-09 · Asthma
What this study did
NCT00370591 · GlaxoSmithKline
2002-12 – 2004-04 · Asthma
What this study did
Other / comorbidity
NCT03055988 · Boehringer Ingelheim
2017-03-29 – 2018-03-26 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01751113 · GlaxoSmithKline
2013-02 – 2013-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01243788 · Fudan University
2009-07 – 2011-10 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01124422 · GlaxoSmithKline
2010-07-19 – 2011-05-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02136875 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2008-07 – 2010-08 · COPD, Chronic Obstructive Pulmonary Disease
What this study did
NCT00984659 · GlaxoSmithKline
2009-10-29 – 2010-07-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00864812 · The Korean Academy of Tuberculosis and Respiratory Diseases
2009-03 – 2010-03 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00633217 · GlaxoSmithKline
2008-03 – 2009-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00355342 · GlaxoSmithKline
2004-04-28 – 2007-09-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00115492 · GlaxoSmithKline
2004-12 – 2007-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00361959 · GlaxoSmithKline
2003-06 – 2006-02 · Pulmonary Disease, Chronic Obstructive
What this study did
Early phase / not applicable (3)
Asthma
NCT03535870 · West-Ward Pharmaceutical
2018-04-26 – 2019-09-10 · Asthma
What this study did
NCT02757209 · Consorzio Futuro in Ricerca
2016-04 – 2018-01 · Asthma, COPD
What this study did
NCT01117116 · National Jewish Health
2010-03 – 2013-09 · Asthma
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Asthma
NCT00318708 · Milton S. Hershey Medical Center
2006-06 – 2009-04 · Asthma
What this study did
Other / comorbidity
NCT00550550 · ALK-Abelló A/S
2007-11 – 2009-09 · Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
What this study did
NCT00562159 · ALK-Abelló A/S
2007-11 – 2009-09 · Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
What this study did
Phase 2 (2)
Asthma
NCT00843193 · GlaxoSmithKline
2008-12-09 – 2010-07-25 · Asthma
What this study did
Other / comorbidity
NCT02569437 · Icahn School of Medicine at Mount Sinai
2014-09 – 2016-08 · Polyp of Nasal Sinus
What this study did
Phase 4 (1)
Asthma
NCT01845025 · Novartis Pharmaceuticals
2013-05 – 2016-05 · Persistent Asthma
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT07537439 · University of Medicine and Pharmacy at Ho Chi Minh City
2026-03-01 – 2026-10-01 · Allergic Rhinitis (AR)
What this study did
NCT02748070 · Stanford University
2015-08 – 2019-07-15 · Chronic Rhinosinusitis, Endoscopic Sinus Surgery, Chronic Rhinosinusitis Without Polyps, Oral Steroids
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fluticasone Propionate: this drugApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol (Ventolin)ApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Betamethasone Dipropionate Emollient Spray (Sernivo)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (Pulmicort)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)
Approved(overall)
Small moleculeGlucocorticoid receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Ortikos)
ApprovedUS marketing discontinued (overall)
—Glucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (targeted-Release) (TARPEYO / Nefecon)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide MMX (Uceris)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Dexamethasone
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Dexamethasone (Dextenza)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued (overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Halobetasol Propionate Lotion (Bryhali)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Hydrocortisone (Cortenema)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Montelukast (Singulair)ApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEWeak signalNo reviewed efficacy summary in this indication
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Relacorilant (Lifyorli)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
Dazucorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
Miricorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibPhase 2Small moleculeBTKPartial signal
NCT05104892: Primary endpoint (LOAC events at Week 12): high-dose rilzabrutinib 36% relative risk reduction vs placebo (OR 0.584, 95% CI 0.253-1.349); low-dose 25% relative risk reduction (OR 0.570, 95% CI 0.202-1.608). missed
SunakimentPhase 2Antibody fragmentTSLPPartial signalFeatured results are safety only in this race
TozorakimabPhase 2Monoclonal antibodyIL-33Partial signal
NCT04570657: Change from baseline to week 16 in clinic pre-bronchodilator FEV1 vs placebo (LSMD, 80% CI): tozorakimab 600 mg +4 mL (-71 to 79), p=0.473; tozorakimab 300 mg +36 mL (-38 to 111), p=0.267 missed
Umeclidinium (Incruse Ellipta)Phase 2Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT01573624: Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873)
NCT01641692: Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1) (Day 15 of each treatment period (up to Study Day 71)): All Study Treatments — Theta1 (mean Baseline): 0.0363 unitless (95% CI 0.028 to 0.045); Theta2 (period Baseline): -0.97 unitless (95% CI -1.06 to -0.881); Omega (mean Baseline): 0.00371 unitless (95% CI 0.002 to 0.005); Omega (period Baseline): 0.149 unitless (95% CI 0 to 0.298); Sigma (Variance of Residual error): 0.0393 unitless (95% CI 0.028 to 0.05)
VerekitugPhase 2Monoclonal antibodyTSLP receptorReliable signal
NCT06196879: Annualized Asthma Exacerbation Rate (AAER) reduction vs placebo (VALIANT): -56% at verekitug 100 mg q12w (p<0.0003); -39% at 400 mg q24w (p<0.02)
AMG 691Phase 1——not yet gradedNo reviewed efficacy summary in this indication
AZD0449Phase 1—JAK1Partial signalFeatured results are safety only in this race
Lodotra (Rayos)Discontinued—Glucocorticoid receptorWeak signal
NCT00686335: Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment (4 weeks and 8 weeks): Lodotra 2.1 number of nocturnal awakenings (Standard Deviation 4.41) vs Cortancyl 10 number of nocturnal awakenings (Standard Deviation 5.45)

Large race: only the 83 furthest-along competitors are listed; 19 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow fluticasone propionate to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 4Rhinitis Allergic, Rhinitis SeasonalNot yet recruiting
Est. primary completion 2026-12 · NCT07817134 · CT.gov ↗
What to watch
2027 (7)
January 2027 (1)
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
May 2027 (1)
Phase 4Acute Wheezing Disorders in Infants Aged 0 to 24 MonthsNot yet recruiting
Est. primary completion 2027-05-31 · NCT07675252 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Eustachian Tube DysfunctionRecruiting
Est. primary completion 2027-06-30 · NCT05275686 · CT.gov ↗
What to watch
Phase 2Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host DiseaseRecruiting
Est. primary completion 2027-06-30 · NCT05922761 · CT.gov ↗
What to watch
September 2027 (1)
Phase 4AsthmaNot yet recruiting
Est. primary completion 2027-09 · NCT07664527 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Chronic Allergic RhinitisNot yet recruiting
Est. primary completion 2027-11 · NCT07918404 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Chronic CoughRecruiting
Est. primary completion 2027-12 · NCT07582549 · CT.gov ↗
What to watch
2028 (1)
August 2028 (1)
Phase 3Chronic Obstructive Pulmonary DiseaseNot yet recruiting
Est. primary completion 2028-08 · NCT06234345 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 March 2026ApprovalFDA approval of Glenmark's generic fluticasone propionate inhalation aerosol 44 mcg
US, FDA · Source ↗